Repro Med Systems (KRMD) financial statements
Repro Med Systems reported revenue of $41M in fiscal 2025, up 14.4% a year over 9 years.
Net income was -$3M and the operating margin -7.2%, against 9.6% in 2016.
Free cash flow was -$470,112.
The diluted share count rose 22% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Repro Med Systems's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $12M | $17M | $23M | $24M | $23M | $28M | $29M | $34M | $41M |
| Cost of revenue | $5M | $5M | $7M | $8M | $9M | $10M | $13M | $12M | $12M | $16M |
| Gross profit | $8M | $8M | $11M | $15M | $15M | $14M | $15M | $17M | $21M | $26M |
| Research and development | $207,282 | $237,486 | $241,124 | $740,475 | $1M | $2M | $5M | $6M | $5M | $4M |
| Selling, general and admin | $6M | $8M | $8M | $10M | $12M | $18M | $21M | $20M | $22M | $23M |
| Operating income | $1M | -$736,251 | $1M | $585,679 | -$1M | -$7M | -$11M | -$10M | -$6M | -$3M |
| Interest expense | $3,412 | $1,886 | — | — | — | — | — | — | — | — |
| Pre-tax income | $1M | -$776,699 | $1M | $696,418 | $1M | -$6M | -$11M | -$10M | -$6M | -$3M |
| Income tax | $359,706 | -$241,700 | $266,380 | $132,069 | -$17,800 | -$2M | -$2M | $4M | $2,893 | $21,890 |
| Net income | $782,864 | -$534,999 | $910,570 | $564,349 | -$1M | -$5M | -$9M | -$14M | -$6M | -$3M |
| EPS (diluted) | $0.02 | -$0.01 | $0.02 | $0.01 | -$0.03 | -$0.10 | -$0.19 | -$0.30 | -$0.13 | -$0.06 |
| Diluted shares | 38M | 38M | 39M | 39M | 42M | 44M | 45M | 46M | 46M | 46M |
| Gross margin | 62.1% | 61.6% | 62.3% | 64.1% | 61.8% | 58.6% | 55.1% | 58.6% | 63.4% | 62.3% |
| Operating margin | 9.6% | -6.0% | 6.7% | 2.5% | -5.2% | -29.9% | -38.6% | -36.0% | -19.2% | -7.2% |
| Net margin | 6.4% | -4.4% | 5.2% | 2.4% | -5.0% | -19.4% | -31.0% | -48.2% | -18.0% | -6.4% |
Balance sheet
Fiscal years, from Repro Med Systems's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $4M | $3M | $4M | $6M | $27M | $25M | $17M | $11M | $10M | $9M |
| Receivables | $1M | $2M | $1M | $3M | $3M | $4M | $4M | $4M | $6M | $6M |
| Inventory | $1M | $1M | $2M | $2M | $7M | $6M | $6M | $3M | $3M | $4M |
| Total current assets | $7M | $7M | $9M | $12M | $38M | $37M | $30M | $20M | $19M | $20M |
| Property, plant and equipment | $996,822 | $932,092 | $858,781 | $611,846 | $1M | $1M | $4M | $4M | $4M | $4M |
| Total assets | $8M | $8M | $11M | $14M | $40M | $41M | $42M | $28M | $27M | $28M |
| Total current liabilities | $1M | $1M | $2M | $2M | $4M | $5M | $7M | $4M | $7M | $8M |
| Total liabilities | $1M | $1M | $2M | $3M | $4M | $5M | $11M | $8M | $10M | $11M |
| Shareholders' equity | $7M | $7M | $9M | $11M | $36M | $37M | $31M | $20M | $17M | $17M |
| Net debt | -$4M | -$3M | -$4M | -$6M | -$27M | -$25M | -$17M | -$11M | -$10M | -$9M |
Cash flow
Fiscal years, from Repro Med Systems's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2M | -$331,616 | $1M | $320,620 | -$743,323 | -$4M | -$5M | -$5M | -$319,718 | $462,405 |
| Capital spending | $121,782 | $203,125 | $297,018 | $201,174 | $920,604 | $346,178 | $3M | $782,949 | $1M | $932,517 |
| Free cash flow | $2M | -$534,741 | $1M | $119,446 | -$2M | -$5M | -$8M | -$6M | -$2M | -$470,112 |
| Stock-based compensation | $114,556 | $205,486 | $366,081 | $1M | $2M | $3M | $3M | $3M | $3M | $3M |
| Share buybacks (net) | — | — | — | -$2,820 | — | — | — | — | — | — |
| Free cash flow margin | 14.6% | -4.3% | 6.8% | 0.5% | -6.9% | -19.9% | -29.3% | -19.9% | -4.8% | -1.1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KRMD.
Open KRMD in InvestinglyQuestions
What was Repro Med Systems's revenue in 2025?
$41M in fiscal 2025, from its 10-K filing.
How much free cash flow does Repro Med Systems generate?
-$470,112 in fiscal 2025 (operating cash flow minus capital spending).
From Repro Med Systems's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.